Evidence map›Paper›PMID 38673048›Full record

ArticleJournal of personalized medicine2024

Identifying Progression-Specific Alzheimer's Subtypes Using Multimodal Transformer.

Diego Machado Reyes, Hanqing Chao, Juergen Hahn, Li Shen, Pingkun Yan, For The Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Diego Machado ReyesDepartment of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0003-2180-3251
Hanqing ChaoDepartment of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0001-5973-2343
Juergen HahnDepartment of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0002-1078-4203
Li ShenDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-5443-0503
Pingkun YanDepartment of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0002-9779-2141
For The Alzheimer's Disease Neuroimaging Initiative

Funding

Ultrascale Machine Learning to Empower Discovery in Alzheimers Disease BiobanksU01AG068057 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Christos Davatzikos, Heng Huang · 2020 to 2026
$20.7M
Advancing Analysis of Multi-omics Data in Alzheimer's Disease ResearchRF1AG063481 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LONG, QI · 2019 to 2020
$3.8M
Artificial Intelligence Strategies for Alzheimer's Disease ResearchR01AG066833 · NIA · UNIVERSITY OF PENNSYLVANIA · PI MOORE, JASON H., RITCHIE, MARYLYN D · 2021 to 2021
$1.6M
Predoctoral Training Program for Alzheimer’s Disease at the Interface of Data Science, Engineering and BiologyT32AG078123 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI Chunyu Wang · 2023 to 2026
$974k
NIA NIH HHS R01 AG066833NIA NIH HHS RF1 AG063481NIA NIH HHS T32 AG078123NIA NIH HHS T32AG078123NIA NIH HHS U01 AG068057NIH HHS AG063481NIH HHS AG066833NIH HHS AG068057
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet its current treatments are limited to stopping disease progression. Moreover, the effectiveness of these treatments remains uncertain due to the heterogeneity of the disease. Therefore, it is essential to identify disease subtypes at a very early stage. Current data-driven approaches can be used to classify subtypes during later stages of AD or related disorders, but making predictions in the asymptomatic or prodromal stage is challenging. Furthermore, the classifications of most existing models lack explainability, and these models rely solely on a single modality for assessment, limiting the scope of their analysis. Thus, we propose a multimodal framework that utilizes early-stage indicators, including imaging, genetics, and clinical assessments, to classify AD patients into progression-specific subtypes at an early stage. In our framework, we introduce a tri-modal co-attention mechanism (Tri-COAT) to explicitly capture cross-modal feature associations. Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (slow progressing = 177, intermediate = 302, and fast = 15) were used to train and evaluate Tri-COAT using a 10-fold stratified cross-testing approach. Our proposed model outperforms baseline models and sheds light on essential associations across multimodal features supported by known biological mechanisms. The multimodal design behind Tri-COAT allows it to achieve the highest classification area under the receiver operating characteristic curve while simultaneously providing interpretability to the model predictions through the co-attention mechanism.

Indexed as

Alzheimer’s diseaseartificial intelligencedisease subtypingmultimodal biomarkertransformer network

Identifiers

PMID38673048
PMCPMC11051083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.